Bimagrumab (BMY338) as a potential treatment for cancer-related cachexia

It is worthy of note that FDA has just granted “breakthrough therapy” to an investigational drug called bimagrumab for the treatment of a rare muscle-wasting disease known as sporadic inclusion body myositis  or sIBM, based on data from a Phase II proof-of-concept study that has shown a substantial benefit for patients treated with bimagrumab compared to placebo. … READ MORE …


Get every new post delivered to your Inbox.

Join 1,454 other followers